Sigma receptor ligands and methods of modulating cellular protein homeostasis using same

Patent metadata

Field	Value
Publication number	US-9388126-B2
Application number	US-201314415061-A
Country	US
Kind code	B2
Filing date	Jul 18, 2013
Priority date	Jul 19, 2012
Publication date	Jul 12, 2016
Grant date	Jul 12, 2016

Abstract

The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention can modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.

First claim

What is claimed is:

1. A compound selected from the group consisting of:
1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine (Compound A);
1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine (Compound B);
1-(3-(4-fluorophenoxy)propyl)-3-(4-trifluoromethylphenyl)guanidine (Compound F);
1-(3-(4-fluorophenoxy)propyl)-3-(4-chlorophenyl)guanidine (Compound G); or
a salt, solvate or N-oxide thereof, and any combinations thereof.

2. A pharmaceutical composition comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt, solvate, or N-oxide thereof, and any combinations thereof.

3. A method of treating breast cancer or prostate cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:
1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine (Compound A);
1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine (Compound B);
1-(3-(4-fluorophenoxy)propyl)-3-(4-trifluoromethylphenyl)guanidine (Compound F); and
1-(3-(4-fluorophenoxy)propyl)-3-(4-chlorophenyl)guanidine (Compound G);

or a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

4. The method of claim 3 , wherein the subject has breast cancer.

5. The method of claim 3 , wherein the subject has prostate cancer.

6. The method of claim 5 , wherein the prostate cancer comprises castrate-sensitive or castrate-insensitive prostate cancer.

7. The method of claim 3 , wherein the subject is human.

8. A method of modulating a Sigma receptor in a subject, wherein the method comprises administering to the subject an effective amount of a compound selected from the group consisting of:
1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine (Compound A);
1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine (Compound B);
1-(3-(4-fluorophenoxy)propyl)-3-(4-trifluoromethylphenyl)guanidine (Compound F); and
1-(3-(4-fluorophenoxy)propyl)-3-(4-chlorophenyl)guanidine (Compound G);
or

a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

9. The pharmaceutical composition of claim 2 , further comprising at least one additional therapeutic agent that inhibits the ubiquitin proteasome system (UPS) or autophagic survival pathway.

10. The pharmaceutical composition of claim 9 , wherein the therapeutic agent is selected from the group consisting of growth factor receptor inhibitors, monoclonal antibodies against growth factor receptors, hormone receptor antagonists, autophagy modulators, ER stress response inhibitors, proteasome inhibitors, p97/VCP inhibitors and any combinations thereof.

11. The compound of claim 1 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine (Compound A), or a salt, solvate or N-oxide thereof, and any combinations thereof.

12. The compound of claim 1 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine (Compound B), or a salt, solvate or N-oxide thereof, and any combinations thereof.

13. The compound of claim 1 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-trifluoromethylphenyl)guanidine (Compound F), or a salt, solvate or N-oxide thereof, and any combinations thereof.

14. The compound of claim 1 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-chlorophenyl)guanidine (Compound G), or a salt, solvate or N-oxide thereof, and any combinations thereof.

15. The pharmaceutical composition of claim 2 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine (Compound A), or a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

16. The pharmaceutical composition of claim 2 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine (Compound B), or a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

17. The pharmaceutical composition of claim 2 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-trifluoromethylphenyl)guanidine (Compound F), or a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

18. The pharmaceutical composition of claim 2 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-chlorophenyl)guanidine (Compound G), or a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

19. The method of claim 3 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine (Compound A), or a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

20. The method of claim 3 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine (Compound B), or a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

21. The method of claim 3 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-trifluoromethylphenyl)guanidine (Compound F), or pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

22. The method of claim 3 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-chlorophenyl)guanidine (Compound G), or a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

23. The method of claim 3 , wherein the subject is a subject in need thereof.

24. The method of claim 19 , wherein the subject is a subject in need thereof.

25. The method of claim 20 , wherein the subject is a subject in need thereof.

26. The method of claim 21 , wherein the subject is a subject in need thereof.

27. The method of claim 22 , wherein the subject is a subject in need thereof.

28. The method of claim 8 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine (Compound A), or a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

29. The method of claim 8 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine (Compound B), or a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

30. The method of claim 8 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-trifluoromethylphenyl)guanidine (Compound F), or pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

31. The method of claim 8 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-chlorophenyl)guanidine (Compound G), or a pharmaceutically acceptable salt, solvate or N-oxide thereof, and any combinations thereof.

Assignees

• Univ Drexel

Inventors

• Kim Felix J
• Salvino Joseph M

Classifications

• A61K31/4035

  Isoindoles, e.g. phthalimide · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• C07C279/18 Primary

  having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings · CPC title

• C07D209/48

  with oxygen atoms in positions 1 and 3, e.g. phthalimide · CPC title

• A61K31/496

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title